Tenpoint Therapeutics Launches with $70 Million Series a Financing to Reverse Vision Loss through Engineered Cell-Based Therapeutics and In Vivo Reprogramming

Tenpoint Therapeutics announced its launch with a $70 million Series A financing to develop its regenerative medicine platform to replace multiple cell types lost to inherited and age-related conditions.